Objective:
To present the 2-year outcomes of the phase 2b PRISM study on the investigational gene therapy 4D-150 for neovascular age-related macular degeneration (nAMD).
Approach:
- Study Design: Phase 2b study focusing on patients with recently diagnosed nAMD.
- Patient Outcomes: Assessment of injection frequency and visual maintenance over 2 years.
Key Findings:
- 66% of patients went 2 years without additional injections, according to the study results.
- 87% had far fewer injections compared to standard-of-care aflibercept, as reported in the findings.
- The majority had 2 or fewer injections over 2 years with maintained vision, based on the study outcomes.
- The safety profile showed minimal iritis in 2 eyes, treated with topical therapy, as noted in the results.
Interpretation:
Limitations:
- Study focused on a subgroup of recently diagnosed patients.
- Long-term follow-up data is limited to 2 years.
Conclusion:
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.